Business Context and Reporting Period
Company: Acadia Healthcare Company, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2017
Event: Entry into a Material Definitive Agreement (Third Repricing Amendment to Credit Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. It focuses exclusively on debt restructuring terms.
| Debt Instrument | Outstanding Balance (as of March 31, 2017) | Previous Eurodollar Rate | New Eurodollar Rate | Previous Base Rate | New Base Rate |
|---|---|---|---|---|---|
| Tranche B-1 Term Loan | $489 million | 3.00% | 2.75% | 2.00% | 1.75% |
| Tranche B-2 Term Loan | $943 million | 3.00% | 2.75% | 2.00% | 1.75% |
Material Changes Versus Prior Period
The primary material change is the reduction in interest rates applicable to the Company's term loans under the Amended and Restated Credit Agreement dated December 31, 2012. The Amendment, executed on May 10, 2017, lowers the Applicable Rate by 25 basis points for Eurodollar Rate Loans and 25 basis points for Base Rate Loans across both Tranche B-1 and Tranche B-2 facilities.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release issued on May 10, 2017, announcing the Amendment. No specific forward-looking guidance or outlook regarding future financial performance is provided in this text.
Risks and Contingencies: The filing notes that the summary of terms is not complete and is qualified by reference to the full Amendment attached as Exhibit 10. No new risks or contingencies are explicitly detailed in the text provided.
Investor Verification Checklist
- Verify the total interest expense savings projected from the 25 basis point reduction on approximately $1.432 billion in term loans.
- Review the full text of the Third Repricing Amendment (Exhibit 10) for any covenants or conditions attached to the rate reduction.
- Confirm the impact of this amendment on the Company's liquidity position and debt service coverage ratios.
- Check the press release (Exhibit 99) for any additional context regarding the Company's capital structure strategy.